ReviewLiver research (Beijing, China)2024
Viral hepatitis E: Clinical manifestations, treatment, and prevention.
Review in Liver research (Beijing, China), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Hepatitis E Virus Infection in Pregnant Women.Microorganisms · 2026Review
- Hepatitis E virus infection: considerations for immunologists and rheumatologists.Rheumatology international · 2026Review
- Hepatitis E virus seroprevalence in South Africa: a multi-site study among HIV-negative and HIV-positive adults and age-stratified children (2-17 Years).BMC infectious diseases · 2026Article
- Paired In-Hospital Dynamics in Hepatitis E: Rapid Transaminase Decline and Persistent Hyperbilirubinemia in a Romanian Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Hepatitis E virus-associated neurological injury and neurotropic cellular mechanisms.Frontiers in cellular and infection microbiology · 2026Review
- Revolutionizing medicine: Exploring the breakthroughs in liver xenotransplantation.Liver research (Beijing, China) · 2025Review
- Simultaneous Detection of HEV, HAstV and SaV in Bivalve Shellfish Using a Novel Real-Time RT-qPCR Method.Food and environmental virology · 2025Article
- Hepatitis E in the pediatric population: An overlooked disease but a genuine concern?Clinical and experimental hepatology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E is a globally distributed infection that varies in seroprevalence between developed and developing regions. In the less developed regions of Asia and Africa, a high seropositivity rate has been reported for hepatitis E virus (HEV) antibodies. Although acute hepatitis E is often self-limited and has a favorable prognosis, some populations experience severe manifestations, which may progress to liver failure. Moreover, some immunocompromised patients are at risk of developing chronic HEV infection and cirrhosis. Proactive screening, reducing misdiagnosis, improving patient management, timely antiviral therapy for severe and chronic cases, and vaccination of high-risk groups are important measures to reduce the morbidity of hepatitis E. This review focused on the clinical presentation, management, and prevention of hepatitis E.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.